Mazurek, Michał, Teutsch, Christine, Diener, Hans-Christoph, Dubner, Sergio J, Halperin, Jonathan L, Ma, Chang-Sheng, Rothman, Kenneth J, Paquette, Miney, Zint, Kristina, França, Lionel Riou et al (show 5 more authors)
(2019)
Safety and effectiveness of dabigatran at 2 years: Final outcomes from Phase II of the GLORIA-AF registry program.
American heart journal, 218.
pp. 123-127.
Text
Mazurek_GLORIA-AF Phase II Final manuscript_16Jan2019.docx - Author Accepted Manuscript Download (364kB) |
Abstract
GLORIA-AF is a large, ongoing, prospective, global registry program run in 3 phases, assessing long-term safety and effectiveness of dabigatran etexilate (dabigatran) in patients with newly diagnosed atrial fibrillation (AF) in clinical practice. This report provides the final analysis of 2-year clinical outcomes of the full cohort of 4873 patients prescribed dabigatran and followed for a mean of 18.0 +/- 9.4 months out of the 15,308 eligible patients enrolled in Phase II (2011-2014). The overall incidence rates per 100 person-years were: stroke 0.65 (95% CI 0.48-0.87), major bleeding 0.97 (0.76-1.23) and myocardial infarction (MI) 0.50 (0.35-0.69), with observed event rates broadly consistent in all study regions, which confirms the sustained safety and effectiveness of dabigatran over 2 years of observation in clinical practice.
Item Type: | Article |
---|---|
Uncontrolled Keywords: | GLORIA-AF Investigators |
Depositing User: | Symplectic Admin |
Date Deposited: | 12 Dec 2019 13:15 |
Last Modified: | 19 Jan 2023 00:12 |
DOI: | 10.1016/j.ahj.2019.08.012 |
Related URLs: | |
URI: | https://livrepository.liverpool.ac.uk/id/eprint/3066094 |